ResearchPUBMEDApr 3
Researchers reviewed studies from the past 10 years about how artificial intelligence and connected care technologies can help patients with rare diseases, especially lysosomal storage disorders (LSDs)—conditions where the body can't break down certain substances properly. The review found that while these digital health tools show promise for helping doctors diagnose and manage these complex diseases, there are still big gaps in the research and not enough real-world examples of these technologies being used in patient care.
WHY IT MATTERSIf you have a lysosomal storage disorder, this research could lead to faster diagnosis, better remote monitoring through connected devices, and AI tools that help your doctors catch problems earlier—potentially improving your long-term care and quality of life.
ResearchPUBMEDApr 3
Researchers tested whether artificial intelligence chatbots like ChatGPT could diagnose rare genetic diseases by comparing them to a traditional diagnostic tool called Exomiser. They tested seven different AI models on over 5,000 real patient cases. The study found that even the best AI chatbots were not as accurate as the existing diagnostic tool at identifying the correct disease.
WHY IT MATTERSIf you're waiting for a diagnosis for a rare genetic disease, this research shows that AI chatbots alone shouldn't replace traditional diagnostic tools—your doctor should continue using proven methods alongside any new technology.
Clinical trialUNITERAREApr 3
Researchers are testing a new combination treatment for advanced kidney cancer that has spread to other parts of the body. The treatment combines two immunotherapy drugs (nivolumab and ipilimumab) with an experimental live biotherapeutic product called EXL01. This Phase 1 trial is now accepting patients to see if adding EXL01 to the standard immunotherapy improves outcomes.
WHY IT MATTERSThis trial offers metastatic renal cell carcinoma patients access to a novel combination approach that may enhance the effectiveness of existing immunotherapies by incorporating a live biotherapeutic product.
Clinical trialUNITERAREApr 3
Researchers are looking for patients with a type of blood cancer called acute lymphoblastic leukemia (ALL) to test a new treatment combination. The study will test whether adding a drug called JZP458 to standard chemotherapy works better than chemotherapy alone. This trial is just starting and will recruit patients beginning in April 2026.
WHY IT MATTERSThis Phase 2 trial is now actively recruiting newly diagnosed ALL patients without the Philadelphia chromosome, offering access to an investigational asparaginase formulation (JZP458) that may have improved tolerability compared to standard asparaginase.
Clinical trialUNITERAREApr 3
Prelude Therapeutics is testing a new drug called PRT12396 in people with certain blood cancers called myeloproliferative neoplasms. This is an early-stage study (Phase 1) to see if the drug is safe and how it works in the body. The study is now accepting patients and is expected to start in April 2026.
WHY IT MATTERSThis trial offers access to a potentially new treatment option for patients with myeloproliferative neoplasms who may have limited alternatives, particularly if they have specific subtypes targeted by this drug.
Clinical trialUNITERAREApr 3
This is a clinical trial testing a blood clotting medicine called Nuwiq in women and girls with hemophilia A who need surgery. Hemophilia A is a rare bleeding disorder where the body doesn't make enough of a protein that helps blood clot. The trial will study how well Nuwiq works and what dose is best for these patients during surgical procedures.
WHY IT MATTERSThis trial is specifically designed for women and girls with hemophilia A undergoing surgery — a population that often receives less research attention than males with the same condition.
Clinical trialUNITERAREApr 3
Triple Hair Inc is recruiting patients for a Phase 3 clinical trial testing a new treatment called TH07 for androgenic alopecia, commonly known as male or female pattern baldness. This is a large-scale study to confirm whether TH07 works better than current treatments. If you have pattern hair loss, you may be eligible to join and help test this potential new therapy.
WHY IT MATTERSThis Phase 3 trial is actively recruiting now, meaning if you have androgenic alopecia, you could potentially enroll and access an investigational treatment while contributing to evidence that could lead to FDA approval.
Clinical trialUNITERAREApr 3
Researchers are testing a new type of cell therapy made from umbilical cord blood to treat T-cell lymphoma that has stopped responding to other treatments. The therapy uses special immune cells called NK cells that are engineered to recognize and attack cancer cells. This is an early-stage study (Phase 1) that is now accepting patients.
WHY IT MATTERSThis trial offers a potential new treatment option for patients with relapsed or refractory T-cell lymphoma who have limited alternatives after standard therapies fail, with enrollment beginning in April 2026.
Clinical trialUNITERAREApr 3
Researchers at the University of Wisconsin are testing a new combination of two cancer treatments called Hepzato Kit and Opdualag for patients with melanoma (a type of skin cancer) that has spread to the liver. This is an early-stage study that started in 2026 and is currently looking for patients to participate. The goal is to see if this combination can help people whose cancer has spread to multiple parts of their body.
WHY IT MATTERSThis trial offers patients with metastatic melanoma and liver involvement access to a novel combination therapy at a major academic medical center, potentially providing treatment options for a particularly aggressive cancer presentation.
Clinical trialUNITERAREApr 3
Researchers are testing a medicine called IGIV 10% to see if it helps people with CIDP, a rare nerve disease that causes weakness and numbness, usually in the legs and feet. IGIV is made from antibodies collected from donated blood. This is a Phase 3 trial, which means the medicine has already been tested in earlier studies and now doctors want to confirm it works well and is safe.
WHY IT MATTERSThis Phase 3 trial is now actively recruiting patients with CIDP — if you have confirmed CIDP diagnosis, you may be eligible to access a potential new treatment option before it becomes widely available.
Clinical trialUNITERAREApr 3
Researchers are testing a new drug called elritercept to see if it works better than a standard treatment (epoetin alfa) for anemia in adults with myelodysplastic syndromes (MDS)—a blood disorder where the bone marrow doesn't make enough healthy blood cells. People in this study have low, very low, or intermediate risk MDS and need regular blood transfusions. The trial is now accepting patients.
WHY IT MATTERSThis Phase 3 trial is actively recruiting adults with MDS who require transfusions, offering access to an investigational treatment that may reduce their dependence on blood transfusions.
Clinical trialUNITERAREApr 3
Researchers at Emory University are looking for pregnant women with sickle cell disease to join a study about blood transfusions. The study will test whether giving blood transfusions during pregnancy can help prevent serious complications for both the mother and baby. This is a Phase 4 trial, which means the treatment has already been tested before and researchers want to learn more about how well it works.
WHY IT MATTERSThis trial is now actively recruiting pregnant women with sickle cell disease — participation could help prevent pregnancy complications like stroke, organ damage, and miscarriage that occur at higher rates in this population.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for phenylketonuria (PKU) — a rare genetic condition that affects how the body processes a protein called phenylalanine — is currently closed and not accepting new applications. The program previously offered up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have PKU and were relying on this $12,000 annual assistance to afford your special diet or medications, you'll need to find alternative financial support resources immediately.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for myasthenia gravis patients is currently closed. This program normally provides up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026, and patients can check the PAN Foundation website for updates on when it might reopen.
WHY IT MATTERSMyasthenia gravis patients who struggle to afford medications and treatments need to know this assistance fund is temporarily unavailable and should monitor for reopening or explore alternative financial aid programs.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for hereditary angioedema (HAE) is currently closed and is not accepting new applications. This program previously provided up to $12,000 per year to help patients afford treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have hereditary angioedema and rely on financial assistance to afford your medications, you'll need to explore alternative funding sources since this major assistance program is temporarily unavailable.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for Fabry disease patients is currently closed and not accepting new applications. This program previously provided up to $12,000 per year to help eligible patients pay for treatment costs. The fund status changed on April 2, 2026, and patients interested in applying should check the PAN Foundation website for updates on when it might reopen.
WHY IT MATTERSFabry disease patients who rely on financial assistance to afford expensive enzyme replacement or substrate reduction therapies have lost access to this $12,000 annual benefit, making it harder to maintain continuous treatment.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for Pompe disease patients is currently closed and not accepting new applications. This program previously provided up to $12,000 per year to help eligible patients pay for treatment costs. The fund status changed on April 2, 2026, and patients should check the PAN Foundation website for updates on when it might reopen.
WHY IT MATTERSPompe disease patients who rely on financial assistance to afford enzyme replacement therapy or other treatments now have one fewer funding option available, which could impact their ability to access care.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance fund for ALS (a disease that affects nerve cells controlling muscles) is currently closed and not accepting new applications. This fund previously provided up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have ALS and were counting on this $12,000 annual assistance from PAN Foundation, you'll need to explore other financial resources immediately, as this fund is no longer available.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for people with primary immunodeficiency is currently closed and not accepting new applications. Primary immunodeficiency is a group of disorders where the immune system doesn't work properly, making it harder to fight infections. When this fund was open, it could help eligible patients pay up to $12,000 per year toward treatment costs.
WHY IT MATTERSPatients with primary immunodeficiency who were relying on this $12,000 annual assistance need to immediately identify alternative funding sources, as this program is no longer accepting applications as of April 2, 2026.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for Duchenne muscular dystrophy patients has closed as of April 2, 2026. This program previously provided up to $12,000 per year to help eligible patients pay for treatment costs. Patients who need financial help with their DMD care should contact PAN Foundation or explore other assistance programs.
WHY IT MATTERSPatients with Duchenne muscular dystrophy who were relying on this $12,000 annual benefit to afford medications or treatments now need to find alternative financial assistance sources immediately.